• Теги
    • избранные теги
    • Компании2322
      • Показать ещё
      Разное482
      • Показать ещё
      Международные организации58
      • Показать ещё
      Страны / Регионы494
      • Показать ещё
      Люди65
      • Показать ещё
      Формат25
      Показатели33
      • Показать ещё
      Издания27
      • Показать ещё
      Сферы3
14 февраля, 16:20

Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance

Teva Pharmaceutical Industries Ltd. (TEVA) reported fourth-quarter 2016 earnings of $1.34 per share (including equity compensation expenses), which beat the Zacks Consensus Estimate of $1.28.

14 февраля, 11:59

НАСА приватизирует МКС

По мере того, как срок эксплуатации Международной космической станции (МКС) приближается к концу, частные космические компании начинают предлагать концепции пост-МКС для будущих исследований и коммерческой деятельности на орбите Земли, пишет The Christian Science Monitor. Их планы являются "музыкой для ушей НАСА”, по выражению издания, которое цитирует одного из руководителей космического агентства:

08 февраля, 17:51

Glaxo (GSK) Misses Q4 Earnings, Revenues Rise Y/Y

Glaxo reported core earnings of 48 cents per American depositary share, missing our consensus estimate of 57 cents.

07 февраля, 22:34

Model N (MODN) Q1 Loss Narrower than Expected, Guides Well

Model N, Inc. (MODN) reported a loss (excluding stock based compensation) of 21 cents per share in first-quarter 2017, which was narrower than the Zacks Consensus Estimate.

Выбор редакции
07 февраля, 16:15

Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO

Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that its present chief executive officer (CEO), Erez Vigodman, is stepping down.

04 февраля, 16:00

How Drug Companies Have Raised Prescription Prices

In this week’s chart, we’re looking at how drug companies have consistently raised prescription prices... and why that business model is under threat today.

03 февраля, 14:59

Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study

Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .

03 февраля, 14:18

Who said tax reform was easy?

Republican efforts to overhaul the tax code for the first time in a generation are facing multiple challenges just two weeks into President Donald Trump’s administration.House Republicans thought they had hit the jackpot in November, when voters handed the GOP full control in Washington nearly five months after they had released a package to slash tax rates for both individuals and businesses. But now, the GOP’s business allies are battling each other over a crucial piece of the House plan. Senators seem less than enthused about that provision, and the administration has sent mixed signals.The issue at the center of all the tax reform chatter right now is called "border adjustability," basically a fancy name for a plan that would exempt exports from taxation while no longer allowing imports to be deducted from a company’s tax bill. House Republicans have repeatedly made the case that a plan that spurs domestic production and gives companies little incentive to flee offshore fits neatly with Trump’s priorities, after the president campaigned against what he called a rigged economy that hurts American workers. “The more Americans understand that our businesses are competing with one hand tied behind their back, the more support this provision will generate,” House Ways and Means Chairman Kevin Brady, who has said the plan he crafted with Speaker Paul Ryan would end a “Made in America” tax, told reporters this week. But perhaps even more importantly, border adjustments would raise more than $1 trillion over a decade, according to multiple independent projections, making the framework key to the GOP’s efforts to revamp the tax code without adding to the deficit. Republicans can’t wait too long to deliver a tax reform measure, or the 2018 midterms could threaten to push the issue to the side. With that in mind, one lobbyist keeping a close eye on the issue predicted Ways and Means would mark up a tax reform bill in July. “I think it’s coming together much faster than I thought,” said Grover Norquist, the founder of Americans for Tax Reform, who noted that Trump shifted his tax reform plan closer to the House proposal during the campaign.Norquist who likes the House GOP plan while not being a huge fan of border adjustments, suggested the president would eventually fall in line behind that idea. “The House Republicans and Trump have put together a plan. It’s coming together. It’s not completely finished, but it’s settled,” Norquist added. So far, Trump has been impossible to pin down on border adjustability. He called the House plan “too complicated” shortly before his inauguration. But then he said he wouldn't rule it out. Last week his press secretary seemed to float the proposal as a way to pay for a wall at the Mexican border. But then he backtracked too. The Senate, where Republicans have been lukewarm at best about the House plan, could weigh in with its own tax reform proposal at some point, potentially scrambling things even more.Until either the House or the Senate produce a more fully fleshed-out plan, most of the attention will likely stay on border adjustability. Industries that are heavily reliant on imports, like retailers and oil refiners, have been bashing the House plan since it was released last June — and have only become more vocal since November’s election. Free-market groups linked to the billionaire Koch brothers have also started to chime in, comparing the framework to a tariff. Members of a newly formed coalition, Americans for Affordable Products, argue that the House plan would both drastically slash profits for retailers and drive up prices for consumers. Most economists say that wouldn’t be the case, because adjusting taxes at the border would strengthen the dollar to even out the losses for retailers and consumers. That’s because it would reduce the demand for imports and increase it for exports, essentially boosting demand for and increasing the value of the dollar. The real losers would be people holding assets in foreign currencies, under that theory.The problem for Republicans who back border adjustments is that could be a tough case to make to voters. “I find it difficult to imagine members of Congress putting their political futures in the hands of the currency markets,” said Ed Kleinbard, the former chief of staff at the Joint Committee on Taxation. “Because if the magic doesn’t work, Joe Consumer does pay more at Walmart.”Brady and House Republicans are just now starting to get a boost from companies that would benefit from the plan, including big-time exporters that might never pay taxes again under such a system. The American Made Coalition, whose members include General Electric and Boeing, have vowed to make the case that border adjustability would be a boon to economic growth. The promise of other benefits from tax reform, like a system that permanently shields offshore profits from taxation, could eventually draw in more multinational corporations even if they’re not helped by border adjustment, according to Paul Oosterhuis, an international tax attorney at Skadden. “The concern is leveling the playing field — so if I’m Pfizer, I can compete with Novartis without one arm tied behind my back,” he said. So far, that kind of message has yet to sway Senate Republicans, who generally have declined to weigh in on border adjustments in much detail. But one key Senate Republican — Majority Whip John Cornyn of Texas — hasn’t been shy in raising concerns about the House plan, warning that the Senate won’t just accept whatever the House produces and openly worrying about the plan’s impact on his state’s refiners.“Most of the senators feel the best thing they could do is say nothing, because politically, there’s not a lot of upside for them to take a position on an issue until they know if the House can’t pass it,” said one tax lobbyist watching the debate. The debate so far has largely sidelined Democrats — who are calling on Republicans to work with them, but also far from troubled to see the GOP already facing so many hurdles. Austan Goolsbee, who was an economic adviser to former President Barack Obama, predicts that Republicans will have to drop tax reform efforts and instead seek a sequel to the tax cuts under former President George W. Bush. But Rep. Richard Neal of Massachusetts, the top Democrat on Ways and Means, said that would give Republicans a pyrrhic victory.“You’re not going to do tax policy with one party and leave the other side out because in the end, if that happens, all that means is the side that doesn’t prevail, they simply do a reset and prepare for the next round,” Neal said Thursday on CNBC.

02 февраля, 17:49

Novartis (NVS) Votubia Gets EU Approval for Label Expansion

Novartis (NVS) wins EU approval for label expansion of Votubia in refractory partial-onset seizures in patients with tuberous sclerosis complex.

02 февраля, 14:42

GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?

GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.

01 февраля, 18:11

Momenta Says District of Delaware Invalidates Teva's MS Drug

Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter .

01 февраля, 15:14

Drug Stocks Rally on Trump Meet with Pharma Bigwigs

Pharma and biotech stocks were up as President Trump discussed a speedier drug approval process, lower regulations and corporate tax reforms.

01 февраля, 01:09

Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting

Following the trend set yesterday, U.S. stocks closed mostly lower on Tuesday but still managed to record monthly gains. Investors continue to weigh the latest policies from the Trump Administration as well as companies' results from the current earnings season.

31 января, 21:08

Biotech Stocks Gain on Latest Trump Drug Price Statements

President Trump continues to double down on his campaign promises, and his latest statements regarding drug prices and regulation have sent biotech stocks higher on Tuesday.

Выбор редакции
31 января, 19:47

Novartis Considers Alcon Spin-Off

Novartis AG (NYSE: NVS; Price: $72.30; Market Capitalization: $189.9 billion) CEO Joe Jimenez stated on January 25, that NVS is considering spinning-off its beleaguered Alcon eye care business.

31 января, 18:57

Trump Meets Drugmakers, Demands Lower Prices

function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTimeout(function(){t(e,i)},0)}}(document.getElementById('vidible_1'),onPlayerReadyVidible); U.S. President Donald Trump on Tuesday called on the pharmaceutical industry to boost U.S. production and lower prices, while also vowing to speed up approval times for new medicines and appoint a new U.S. Food and Drug Administration leader soon. Shares of five of the six drug companies at the White House meeting with Trump were up more than 1 percent on average following the president’s remarks, compared with a 0.5 percent drop in the broad S&P 500. The Nasdaq Biotech Index was up 1.1 percent, reversing earlier losses, and the S&P 500 health care index gained 0.7 percent. Attending the meeting were the CEOs of Novartis AG, Merck & Co Inc, Johnson & Johnson, Celgene Corp, Eli Lilly & Co and Amgen Inc as well as the head of the Pharmaceutical Research and Manufacturers of America lobbying group. Trump told the drugmakers that pricing had been “astronomical.” “We have to get prices down for a lot of reasons. We have no choice, for Medicare and Medicaid,” Trump said at the meeting, citing the nation’s government insurance programs for the elderly, the poor and the disabled that together are the largest U.S. purchaser of medications. Trump also said currency devaluation by other countries had increased drugmakers’ outsourcing their production and called on the companies to make more of their products in the United States. He added that foreign countries must pay fair share for drug development costs. “We’re going to end global freeloading,” Trump said. Novartis CEO Joe Jimenez, who is chairman-elect of the industry lobbying group, said last week that he wanted to talk to Trump about efforts to develop pricing models that would pay for clinical results rather than a flat price per pill, as well as plans to replace the Affordable Care Act, which is popularly known as “Obamacare.” Trump spooked investors in the pharmaceuticals and biotech sectors by saying on Jan. 11, before his inauguration, that drug companies were “getting away with murder” on what they charged the government for medicine and that he would do something about it. That prompted the pharmaceutical lobbying group to unveil a new TV marketing campaign last week to improve its image by focusing attention on strides in research. Company executives, meanwhile, have tried to tread a careful line in defending their industry while expressing optimism that the United States would continue to reward scientific advances. (Additional reporting by Eric Beech, Ben Hirschler and John Miller; Editing by Lisa Von Ahn) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

31 января, 18:57

Trump Meets Drugmakers, Demands Lower Prices

function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTimeout(function(){t(e,i)},0)}}(document.getElementById('vidible_1'),onPlayerReadyVidible); U.S. President Donald Trump on Tuesday called on the pharmaceutical industry to boost U.S. production and lower prices, while also vowing to speed up approval times for new medicines and appoint a new U.S. Food and Drug Administration leader soon. Shares of five of the six drug companies at the White House meeting with Trump were up more than 1 percent on average following the president’s remarks, compared with a 0.5 percent drop in the broad S&P 500. The Nasdaq Biotech Index was up 1.1 percent, reversing earlier losses, and the S&P 500 health care index gained 0.7 percent. Attending the meeting were the CEOs of Novartis AG, Merck & Co Inc, Johnson & Johnson, Celgene Corp, Eli Lilly & Co and Amgen Inc as well as the head of the Pharmaceutical Research and Manufacturers of America lobbying group. Trump told the drugmakers that pricing had been “astronomical.” “We have to get prices down for a lot of reasons. We have no choice, for Medicare and Medicaid,” Trump said at the meeting, citing the nation’s government insurance programs for the elderly, the poor and the disabled that together are the largest U.S. purchaser of medications. Trump also said currency devaluation by other countries had increased drugmakers’ outsourcing their production and called on the companies to make more of their products in the United States. He added that foreign countries must pay fair share for drug development costs. “We’re going to end global freeloading,” Trump said. Novartis CEO Joe Jimenez, who is chairman-elect of the industry lobbying group, said last week that he wanted to talk to Trump about efforts to develop pricing models that would pay for clinical results rather than a flat price per pill, as well as plans to replace the Affordable Care Act, which is popularly known as “Obamacare.” Trump spooked investors in the pharmaceuticals and biotech sectors by saying on Jan. 11, before his inauguration, that drug companies were “getting away with murder” on what they charged the government for medicine and that he would do something about it. That prompted the pharmaceutical lobbying group to unveil a new TV marketing campaign last week to improve its image by focusing attention on strides in research. Company executives, meanwhile, have tried to tread a careful line in defending their industry while expressing optimism that the United States would continue to reward scientific advances. (Additional reporting by Eric Beech, Ben Hirschler and John Miller; Editing by Lisa Von Ahn) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

31 января, 18:27

По итогам декабря 2016 года 58% препаратов, реализованных на рынке, являлись российскими

По данным аудита фармацевтического рынка России DSM Group, объём коммерческого рынка лекарственных препаратов в декабре 2016 г. составил 70,6 млрд. руб. (с НДС). По сравнению с ноябрём ёмкость рынка увеличилась на 30,3%. В сравнении с декабрём 2015 г. в текущем году объёмы продаж увеличились на 34,8%. "Средняя стоимость упаковки лекарственного препарата на коммерческом рынке России в декабре 2016 г. по сравнению с ноябрём снизилась на 0,1% и составила 151,8 руб. Согласно индексу Ласпейреса, в течение декабря 2016 года цены в рублях возросли на 1,3%. В долларовом выражении индекс цен также повысились на 2%. Всего же с начала 2016 года инфляция цен на лекарства в аптеках страны составила 5% в рублевом выражении и 11,4% в долларах США", - отмечает эксперт фармацевтического рынка, генеральный директор DSM Group Сергей Шуляк. Структура коммерческого рынка лекарственных препаратов в декабре 2016 г. по ценовым сегментам претерпела ряд изменений по сравнению с аналогичным периодом 2015 г. На 0,3% относительно декабря 2015 г. снизилась доля сегмента лекарств со средней стоимостью упаковки 50-150 руб. (за месяц доля увеличилась на 0,1%). На 1,1% увеличился удельный вес группы лекарств с ценовым диапазоном 150-500 руб. (с 48,1% в декабре 2015 г. до 49,2% в декабре 2016 г.). За месяц доля рассматриваемого ценового сектора выросла на 0,8%, что сопровождалось заметным (на 3,6%) увеличением средней цены упаковки лекарств (в итоге средняя стоимость составила 267,8 руб./упак.). Доля дорогостоящих препаратов в декабре 2016 г. составила 29,1%, что на 0,9% меньше удельного веса группы в предыдущем месяце и на 0,5% меньше, чем в декабре 2015 г. При этом средняя стоимость упаковки в декабре 2016 г. в сравнении с аналогичным периодом 2015 г. выросла на 2,6% и оставила 913,5 руб./упак. "По итогам декабря 2016 г. 58% препаратов, реализованных на рынке, являлись отечественными (в натуральных единицах измерения), однако в виду своей невысокой цены относительно импортных лекарств, в стоимостном выражении они занимали лишь 30%. Коммерческий сегмент рынка по итогам декабря 2016 г. на 46% был представлен рецептурными препаратами и на 54% безрецептурными лекарствами", говорит эксперт фармацевтического рынка, генеральный директор DSM Group Сергей Шуляк. Рейтинг компаний по стоимостному объему продаж в декабре 2016 г. возглавила компания Bayer, на втором месте - Sanofi, на третьем месте - Novartis. ТОП брендов лекарственных средств: по стоимостному объёму аптечных продаж в России по итогам декабря 2016 г. лидировал препарат "Ингавирин" (1,32% от совокупных аптечных продаж), на втором месте "Кагоцел" (1,22%) и третьем месте "Нурофен" (0,80%). Объём российского аптечного рынка БАД в стоимостном выражении в декабре 2016 г. увеличился на 19,4% относительно ноября и составил 3,3 млрд. руб. В натуральном выражении объём аптечного рынка БАД в первом зимнем месяце 2016 г. увеличился на 30,3% по сравнению с аналогичным периодом 2015 г. и составил 27,9 млн. упаковок. Средневзвешенная цена упаковки БАД в декабре 2016 г. по сравнению с ноябрем снизилась на 0,8% и составила 118,5 руб.(http://gmpnews.ru/2017/01...)

31 января, 18:03

Trump tells drugmakers he'll tackle prices

President Donald Trump pledged Tuesday to expedite drug approvals and force foreign nations to pay their fair share for drugs manufactured in the U.S.“We’re gonna be changing a lot of the rules. We’re going to be ending global free loading,” Trump said during a White House meeting with pharmaceutical industry executives. “Foreign price controls reduce the resources of American drug companies to finance drug and R&D innovation.” Trump added that “it’s very unfair to this country” and promised an America-first trade policy. “Our trade policy will prioritize that foreign countries pay their fair share for U.S.-manufactured drugs so our drug companies have greater financial resources to accelerate the development of new cures,” he said. “And I think it’s so important.” He added that his administration would also focus on getting the Food and Drug Administration to speed up drug approvals. "We're going to get the approval process much faster," Trump said.

31 января, 17:55

Incyte and Calithera Enter into Deal for Oncology Candidate

Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.